Mateon to Develop its OT-101, a Phase 3 Clinical Drug Candidate, Initially Against COVID-19

by NASDAQ Market News March 18, 2020

NASDAQ Market News
Click here to email author

Synairgen to start trial of SNG001 in COVID-19 imminently

$1.7 Billion HLA Typing Market Outlook, 2025; by Technology (PCR, NGS, Sanger Sequencing), Product, Application, End-user and Region

Ads